The utility of spirometry in the diagnosis of reversible airways obstruction.
Patients with suspected reversible airways obstruction (RAO) sometimes report subjective benefit after bronchodilator treatment despite no objective spirometric improvement. One possible explanation for this is improvement in volume-related or plethysmographic parameters in the absence of spirometric improvement. One hundred patients with RAO were assessed before and after inhaled bronchodilator to determine the prevalence of improvement by plethysmographic parameters in the absence of improvement in spirometric parameters. Spirometry alone (FEV1, FVC, and FEF25-75%) identified reversibility of airflow limitation in 82 patients. Reversibility was identified by body plethysmography (specific conductance [SGaw], thoracic gas volume [TGV], and isovolume maximum expiratory flow rates [IVMEF]) in 15 of the remaining patients. The percent predicted FEF25-75% at baseline was higher in patients who required plethysmography to identify reversibility, but could not be used to predict the lack of a spirometric response for any individual patient. We conclude that spirometry alone fails to identify reversibility in approximately 15 percent of patients, and that most of these patients can be identified by additional plethysmographic measurements of volume-related parameters. At any one point in time, multiple tests must be used together to adequately identify the majority of patients with reversible airways obstruction. Improvement in volume-related parameters may explain why some patients with RAO improve subjectively with bronchodilators but show no spirometric improvement.
Smith
H R
HR
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver.
Irvin
C G
CG
Cherniack
R M
RM
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000402:Airway Obstruction / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D000403:Airway Resistance / Q000187:drug effects; D000704:Analysis of Variance; D001993:Bronchodilator Agents / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D010993:Plethysmography, Whole Body / Q000295:instrumentation / Q000706:statistics & numerical data; D012129:Respiratory Function Tests / Q000295:instrumentation / Q000706:statistics & numerical data; D013147:Spirometry / Q000295:instrumentation / Q000706:statistics & numerical data
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents